PMID- 19330168
OWN - NLM
STAT- MEDLINE
DCOM- 20090806
LR  - 20220317
IS  - 0214-0934 (Print)
IS  - 0214-0934 (Linking)
VI  - 22
IP  - 2
DP  - 2009 Mar
TI  - Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
PG  - 93-106
LID - 10.1358/dnp.2009.22.2.1334452 [doi]
AB  - The HER2 (ERBB2) oncogene encodes a transmembrane tyrosine kinase receptor that 
      has evolved as a major biomarker of invasive breast cancer and target of therapy 
      for the disease. HER2 gene amplification or protein overexpression is encountered 
      in approximately 20% of newly diagnosed breast cancers and is a validated adverse 
      prognostic factor with a mean relative risk for overall survival of 2.74. A 
      series of quality assurance recommendations for the marketed slide-based HER2 
      testing approaches including immunohistochemistry (IHC), fluorescence in situ 
      hybridization (FISH) and chromogenic in situ hybridization (CISH/SISH) has 
      recently been published by the American Society of Clini- cal Oncology - College 
      of American Pathologists (ASCO-CAP). Testing issues, such as the impact of 
      chromosome 17 polysomy and local versus central HER2 testing and emerging novel 
      HER2 testing techniques, including messenger RNA (mRNA)-based testing by real 
      time polymerase chain reaction (RT-PCR) and DNA microarray methods, HER2 receptor 
      dimerization, phosphorylated HER2 receptors and HER2 status in circulating tumor 
      cells are of current interest in the management of breast cancer. Also of 
      significant interest are the evolving lists of biomarkers proposed to predict 
      resistance to the major anti-HER2 therapies, trastuzumab and lapatinib.
CI  - Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
FAU - Ross, Jeffrey S
AU  - Ross JS
AD  - Department of Pathology, Laboratory Medicine, Albany Medical College, Albany, New 
      York, USA. rossj@mail.amc.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Drug News Perspect
JT  - Drug news & perspectives
JID - 8809164
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Quinazolines)
RN  - 0VUA21238F (Lapatinib)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*diagnosis/*metabolism
MH  - *Cytological Techniques
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression
MH  - Genes, erbB-2/*drug effects
MH  - *Genetic Techniques
MH  - Guidelines as Topic
MH  - Humans
MH  - Lapatinib
MH  - Prognosis
MH  - Quinazolines/*therapeutic use
MH  - Receptor, ErbB-2/*analysis
MH  - Trastuzumab
RF  - 153
EDAT- 2009/03/31 09:00
MHDA- 2009/08/07 09:00
CRDT- 2009/03/31 09:00
PHST- 2009/03/31 09:00 [entrez]
PHST- 2009/03/31 09:00 [pubmed]
PHST- 2009/08/07 09:00 [medline]
AID - 1334452 [pii]
AID - 10.1358/dnp.2009.22.2.1334452 [doi]
PST - ppublish
SO  - Drug News Perspect. 2009 Mar;22(2):93-106. doi: 10.1358/dnp.2009.22.2.1334452.